Recent Updates
Recently added Catalysts
RDY Neutral Sentiment Score: 55/100

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.co

Key Takeaway: Dr. Reddy's Laboratories provided clarification regarding a news article that speculated on their potential acquisition of Novartis AG's stake in Novartis India. The company stated that it does not comment on market speculations and confirmed that no relevant information necessitating a disclosure is available at this time. The clarification aims to maintain transparency as per the SEBI Listing Regulations, which govern the company's reporting responsibilities. Dr. Reddy’s emphasized their commitment to disclose any material events promptly.

Market Sentiment Analysis

CONCERNS & RISKS

  • Dr. Reddy's Laboratories is currently involved in unconfirmed market speculation.
  • The company refrains from commenting on potential acquisitions, which may cause uncertainty among investors.

Full Press Release Details

Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
Limited (Scrip Code: 500124)
York Stock Exchange Inc. (Stock Code: RDY)
IFSC Ltd (Stock Code: DRREDDY)
Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - clarification
on reported news article published in electronic media, https://www.cnbctv18.com/
is in reference to Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing
Regulations") regarding a news article published in electronic media https://www.cnbctv18.com
on February 17, 2024, with the heading "Novartis AG conducting strategic review of India-listed
business, no decision on outcome yet: Novartis India".
said news article, inter alia, talks about "Dr Reddy's is likely in a race to acquire Novartis AG's stake in Novartis India.
The sources said Dr Reddy's plans to acquire the domestic-focused portfolio and may offer controlling premium". In this regard,
please note that the Company does not comment on market speculations and there is currently no such event or information which requires
a disclosure under Regulation 30 of the SEBI Listing Regulations.
compliance with Regulation 30 of the SEBI Listing Regulations, the Company makes prompt disclosures, as and when any event or information
is considered material or warrants such disclosure under the said Regulations.
is for your information.
Dr. Reddy's Laboratories Limited
Secretary, Compliance Officer and Head-CSR

Frequently Asked Questions

What is the stock code for Dr. Reddy's Laboratories?

The stock code for Dr. Reddy's Laboratories is 500124.

What was the news article about regarding Novartis AG?

The article discussed Novartis AG reviewing its business in India, with Dr. Reddy's potentially acquiring its stake.

Is there any confirmation about Dr. Reddy's acquisition plans?

Dr. Reddy's has not confirmed any acquisition plans or commented on market speculations.

What is Regulation 30 of SEBI?

Regulation 30 of SEBI mandates disclosure of material events related to listed companies.

Who is responsible for regulatory compliance at Dr. Reddy's?

The Secretary, Compliance Officer, and Head-CSR handle regulatory compliance at Dr. Reddy's.

Last updated: Feb 17, 2024